It has recently signed a licensing agreement with Bristol-Myers Squibb for a Phase I cancer antibody, IPH2102. Accordingly, Bristol-Myers Squibb will be responsible for the development of the compound and Innate Pharma will collaborate on the pre-clinical and clinical work with notably the carrying out a Phase II trial in acute myeloid leukemia.
In addition, Innate Pharma has an antibody program licensed to Novo Nordisk A/S - IPH2201 (NN8765) - for a development in inflammation, stemming from a broader collaboration.